1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Baxter International Inc.

Baxter International Inc.

BAX
Baxter International Inc.US flagNew York Stock Exchange
18.54
USD
-0.14
- -
9.58BMarket Cap
Baxter International Inc.
BAX
(New York Stock Exchange)

Recent

price

18.54

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
21.77
24.42
25.29
17.34
19.78
18.29
18.61
19.49
20.78
22.32
22.93
24.2
19.95
20.47
20.85
21.92
22.02
Revenue per Share
2.41
3.91
4.22
3.71
4.61
1.78
9.09
1.11
2.9
1.97
2.17
2.56
-4.83
5.25
-1.27
-1.87
-2.14
Basic EPS, GAAP
5.09
4.95
5.64
5.89
5.93
3.25
3.03
3.16
3.78
4.13
3.67
4.43
1.89
3.4
1.97
1.63
2.43
Free Cash Flow per Basic Share
1.17
1.25
1.46
1.88
2.02
1.67
0.49
0.58
0.7
0.83
0.93
1.06
1.14
1.16
1.16
0.68
0.52
Dividend per Share
14.59
17.77
21
23.08
25.66
19.02
27.26
27.93
29.51
32.22
33.42
35.35
29.23
33.2
30.61
28.05
27.95
Book Value per Share
7.26
6.48
6.65
3.66
6.66
8.86
8.38
8.55
6.47
6.7
7.54
-16.95
-14.58
-6.41
-6.81
-6.23
-6.03
Tangible Book Value per Share
590
569
551
543
542
545
546
543
534
509
509
502
504
506
510
513
514
Basic Weighted Avg Shares
12,843
13,893
13,936
9,413
10,719
9,968
10,163
10,584
11,099
11,362
11,673
12,146
10,057
10,360
10,636
11,244
11,320
Sales/Revenue/Turnover
16.63
21.2
19.88
5.27
6.12
4.5
7.33
12.17
14.27
15.6
13.68
11.07
-0.33
6.82
4.13
1.57
1.63
Operating Margin (%)
685
670
712
635
792
759
800
750
771
789
823
867
1,072
984
997
981
971
Depreciation Expense
1,420
2,224
2,326
2,012
2,497
968
4,965
602
1,546
1,001
1,102
1,284
-2,433
2,656
-649
-957
-1,098
Net Income, GAAP
24.5
19.69
19.56
16
6.73
8.18
- -
44.64
4.02
- -
14.09
7.44
- -
25.21
- -
- -
150.42
Effective Tax Rate (%)
11.06
16.01
16.69
21.37
23.3
9.71
48.85
5.69
13.93
8.81
9.44
10.57
-24.19
25.64
-6.1
-8.51
-9.7
Profit Margin (%)
3,948
3,793
4,501
4,947
4,125
6,046
3,830
4,442
3,145
4,273
5,078
4,636
3,266
3,097
2,342
3,902
3,154
Working Capital
4,363
4,749
5,580
8,126
7,331
3,922
2,779
3,509
3,481
5,319
6,287
17,671
15,679
11,354
10,617
9,696
8,845
LT Debt
6,796
6,828
6,978
8,486
8,156
8,865
8,280
9,116
7,866
7,912
8,726
9,121
5,895
8,468
7,024
6,102
6,016
Total Equity
13.03
18.5
16.12
2.55
3.4
2.45
- -
5.9
12.44
- -
9.26
5.75
- -
2.3
- -
- -
- -
Return on Invested Capital (%)
11.7
15.75
14.61
10.91
11.87
5.53
- -
3.57
8.62
- -
5.3
4.89
- -
9.62
- -
- -
2.23
Return on Capital (%)
17.07
23.76
21.45
16.69
18.88
7.97
39.33
4.01
10
6.23
6.6
7.39
-14.98
16.85
-4.01
-6.38
-7.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
755
84
842
LT Borrowings
8,747
9,473
8,621
LT Finance Leases
210
223
224
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
514
514
516
Market Capitalization
11,687
9,823
8,635

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,933
6,872
6,847
Cash, Cash Equivalents & STI
1,726
1,966
2,017
Accounts Receivable, Net
1,777
1,861
1,698
Inventories
2,460
2,232
2,316
Total Current Liabilities
3,775
2,970
3,693
Payables & Accruals
3,020
2,182
2,851
ST Debt
755
84
842
Deferred Revenue
- -
141
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.67%
-3.47%
-13.13%
Free Cash Flow
-0.81%
-3.19%
-16.82%
Net Income, GAAP
-10.24%
-111.82%
47.46%
Sales/Revenue/Turnover
1.43%
-0.35%
5.72%
Total Cash Common Dividend
-2.72%
-3.58%
-41.02%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,490
2,694
2,699
2,753
10,636
2025
2,625
2,810
2,835
2,974
11,244
2026
2,701
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
-0.62
0.27
-1
-1.27
2025
0.24
0.18
-0.09
-2.19
-1.87
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.29
0.29
0.29
1.16
2025
0.17
0.17
0.17
0.17
0.68
2026
0.01
- -
- -
- -
- -
Similar Companies
Poly Medicure Limited (POLYMED.NS)
Safe Orthopaedics S.A. (ALSAF.PA)
Elekta AB (publ) (EKTAY)
Kossan Rubber Industries Bhd (7153.KL)
AngioDynamics, Inc. (ANGO)
NEXGEL, Inc. (NXGL)
Business
Baxter International Inc specializes in medical products and therapies, healthcare system technologies, and pharmaceuticals. The company's main products include advanced surgical technologies under its Advanced Surgery division, infusion therapies and intravenous delivery systems under Infusion Therapies and Technologies, and hospital pharmaceuticals focusing on pain management, critical care, anti-infection, and oncology. Its Healthcare Systems and Technologies segment operates through divisions such as Front Line Care, Digital Platform and Innovations, Care and Connectivity Solutions, and Global Services. Baxter serves healthcare providers globally, offering products used at the hospital bedside, operating rooms, intensive care units, home care, and alternate care settings. Founded in 1931 and headquartered in Deerfield, Illinois, Baxter operates worldwide and emphasizes innovation to improve patient outcomes and operational efficiency. Recently, Baxter has undergone significant strategic transformations including the spin-off of its Renal Care and Acute Therapies global business units to establish a separate publicly traded company, streamlining its commercial and manufacturing footprint to enhance business performance, and reviewing strategic alternatives for its BioPharma Solutions business. In 2025, the company appointed Andrew Hider as CEO to advance continuous improvement and sustainable growth. Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation connected patient monitoring device, and achieved recognition with a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative in categories including IV Solutions, Nutrition Solutions, and Premix Drugs. The company also completed the integration of its Hill-Rom acquisition and continues to focus on operational simplification by reducing distribution centers and enhancing digital health solutions. Baxter reported third-quarter 2025 sales growth driven by Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments with ongoing investments in R&D to support steady product launches and innovation.

Company News

APIChat

  • seekingalpha.com

    Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • marketbeat.com

    Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting

  • seekingalpha.com

    Baxter International Still Has A Path To Upside

  • seekingalpha.com

    Madison Small Cap Fund Q1 2026 Portfolio Activity

  • seekingalpha.com

    Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript

  • zacks.com

    BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract

  • zacks.com

    Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

  • zacks.com

    Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

  • reuters.com

    Baxter beats quarterly expectations on strong demand for medical devices

  • gurufocus.com

    Is Baxter International (BAX) 53.0% Undervalued After Q1 2026 Earnings Beat? Adjusted EPS $0.36 vs $0.11 est; Revenue $2.70B vs $2.62B est -- GF Score 57/100

  • businesswire.com

    Baxter Reports First-Quarter 2026 Results

  • zacks.com

    Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline

  • zacks.com

    Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again?

  • defenseworld.net

    Baxter International (NYSE:BAX) vs. GN Store Nord (OTCMKTS:GNNDY) Head-To-Head Analysis

  • zacks.com

    Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

  • businesswire.com

    Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026

  • businesswire.com

    Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

  • defenseworld.net

    Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of “Hold” from Brokerages

  • defenseworld.net

    Reviewing Zynex (NASDAQ:ZYXI) and Baxter International (NYSE:BAX)

  • zacks.com

    Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy